<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">9949285</PMID>
        <DateCompleted>
            <Year>1999</Year>
            <Month>04</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0378-7346</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>47</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1999</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Gynecologic and obstetric investigation</Title>
                <ISOAbbreviation>Gynecol. Obstet. Invest.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Granulosa cell tumor of the ovary. Immunohistochemical evidence of low proliferative activity and virtual absence of mutation of the p53 tumor-suppressor gene.</ArticleTitle>
            <Pagination>
                <MedlinePgn>133-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND AND METHODS" NlmCategory="METHODS">Because the use of immunohistochemistry in the diagnosis of granulosa cell tumor (GCT) has not been fully explored, routinely processed (formalin-fixed, paraffin-embedded) tissue from 11 GCT, adult type, was investigated immunohistochemically (ABC method) with a broad spectrum of antibodies against various markers, including p53 and Ki-67. All of the tumors exhibited typical morphology, were limited to the ovary (stage I), and 7 cases followed a benign clinical course.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All the tumors exhibited strong expression of vimentin, but most other antigens (including smooth muscle actin) were expressed infrequently by a minority of tumor cells or not at all. Tumor cells in 9 GCT expressed inhibin A. All the tumors exhibited very low proliferative activity, fewer than 10% of the tumor cell nuclei being stained by the antibody MIB-1 (Ki-67 antigen). The antibody D07 revealed marked overexpression of p53 protein in only one tumor. Clinical outcome was not found to be related to immunophenotypic differences.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnosis of GCT should be based primarily on the typical morphology revealed by conventional stains, but additional immunohistochemical staining with a small panel of selected antibodies (for example, against keratin, vimentin, and inhibin A) may be helpful in a few cases. The very low proliferative activity and the lack of overexpression of p53 protein are consistent with the benign clinical behavior of the majority of GCT.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Horny</LastName>
                    <ForeName>H P</ForeName>
                    <Initials>HP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, University of Tübingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marx</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kröber</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lüttges</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaiserling</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dietl</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Gynecol Obstet Invest</MedlineTA>
            <NlmUniqueID>7900587</NlmUniqueID>
            <ISSNLinking>0378-7346</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014746">Vimentin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57285-09-3</RegistryNumber>
                <NameOfSubstance UI="D007265">Inhibins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002455" MajorTopicYN="Y">Cell Division</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016158" MajorTopicYN="N">Genes, p53</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006106" MajorTopicYN="N">Granulosa Cell Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007265" MajorTopicYN="N">Inhibins</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>3</Hour>
                <Minute>2</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>3</Hour>
                <Minute>2</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9949285</ArticleId>
            <ArticleId IdType="pii">10077</ArticleId>
            <ArticleId IdType="doi">10.1159/000010077</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
